NCT02780011View on ClinicalTrials.gov

Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2015

Primary Completion Date

September 30, 2018

Study Completion Date

September 30, 2018

Conditions
CD30-positive LymphomaCD30-positive Solid Tumor
Interventions
DRUG

Brentuximab Vedotin

Antibody-drug conjugate composed of the anti-CD30 chimeric immunoglobulin G1 monoclonal antibody cAC10 and the antimicrotubule drug monomethyl auristatin E connected by a protease-cleavable linker.

DRUG

Alsertib

Aurora A kinase inhibitor

Trial Locations (1)

77030

Houston Methodist Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

collaborator

The Methodist Hospital Research Institute

OTHER

lead

Eric Bernicker, MD

OTHER